Is There Something Else Beyond Cost-Effectiveness Analysis for Public Health Decision Making?

Clicks: 400
ID: 72687
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #4 of 51 articles by views in value in health regional issues

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Healthcare costs are a concern for the sustainability of health systems in both rich and poor countries. Achieving a balance between the aspirations of payers and the manufacturers of new technologies is a challenge for democratic societies. Evidence about the efficacy and effectiveness of a new intervention is a fundamental aspect for its inclusion, but additional information about organization, implementation, and feasibility is required. Economic evaluations, especially cost-effectiveness analyses (CEA), help inform the choice of a particular health intervention, but they are not the only input for decision making (DM). Use of CEA is relatively recent but has quickly become widespread. CEA techniques have evolved into increasingly complex and sophisticated methods intended to reflect reality closely but, at the same time, their results have become more difficult to verify and validate. In developed countries, CEA results have generated intense debates, but in developing countries, these reflections are still weak due to lack of technical capacity. Competing perspectives on CEAs exist and can heavily influence the DM process. The use of CEAs and the interpretation of their results requires critical analysis, especially when public funds are to be invested. Here, we present a perspective on the use of CEAs for DM that arises from our experience of its use in developing countries and requires the consideration of other rationalities, in addition to the economic one, for DM.
Reference Key
castaedaorjuela2019isvalue Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Castañeda-Orjuela, Carlos;García-Molina, Mario;De la Hoz-Restrepo, Fernando;
Journal value in health regional issues
Year 2019
DOI
S2212-1099(19)30619-3
URL
Keywords
public health technology assessment decision making cost-benefit analysis biomedical

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.